Scientists discover 'fickle' DNA changes in brain
Interesting paper just came out showing epigenetic changes in the DNA of non-dividing neurons.
Related Links
How healthy is Helocos Biosciences
Friday, May 28, 2010 | By DNAmite
One very strange company in the sequencing area is behaving very strange:
http://www.reuters.com/article/idCNSGE64G0LN20100517?rpc=44
* To shift focus to diagnostics business
* Says 50 pct of remaining workforce on NIH funding
* Says to continue to support current installed base
* Shrs up 11 pct after market
May 17 (Reuters) - Helicos BioSciences Corp (HLCS.O: Quote, Profile, Research, Stock Buzz) said it cut half its total workforce to save on operating costs as the life-sciences company shifts focus to its diagnostics business as part of a restructuring plan.
Helicos said half of the remaining 40 employees are supported by National Institutes of Health funding on research designed to further improve its proprietary DNA and RNA single molecule sequencing technology.
The company, which focuses on genetic analysis technologies, had said in September last year failure to raise capital would have a material adverse impact on its ability to continue as a going concern.
Helicos, which would shift a significant portion of its resources towards development of diagnostics strategy, said it would continue to support its current installed base with collaborative activities, reagent supply and service support.
Shares of the company were up 11 percent at $0.62 in after-market trade. They closed at $0.56 Monday on Nasdaq. (Reporting by Shobhana Chadha in Bangalore; Editing by Unnikrishnan Nair)
http://www.reuters.com/article/idCNSGE64G0LN20100517?rpc=44
Helicos BioSciences cuts half of workforce
* Says cut about 40 positions in Q4* To shift focus to diagnostics business
* Says 50 pct of remaining workforce on NIH funding
* Says to continue to support current installed base
* Shrs up 11 pct after market
May 17 (Reuters) - Helicos BioSciences Corp (HLCS.O: Quote, Profile, Research, Stock Buzz) said it cut half its total workforce to save on operating costs as the life-sciences company shifts focus to its diagnostics business as part of a restructuring plan.
Helicos said half of the remaining 40 employees are supported by National Institutes of Health funding on research designed to further improve its proprietary DNA and RNA single molecule sequencing technology.
The company, which focuses on genetic analysis technologies, had said in September last year failure to raise capital would have a material adverse impact on its ability to continue as a going concern.
Helicos, which would shift a significant portion of its resources towards development of diagnostics strategy, said it would continue to support its current installed base with collaborative activities, reagent supply and service support.
Shares of the company were up 11 percent at $0.62 in after-market trade. They closed at $0.56 Monday on Nasdaq. (Reporting by Shobhana Chadha in Bangalore; Editing by Unnikrishnan Nair)
Sequenom Introduces the MassARRAY Analyzer 4 System. Next-Generation Proprietary Platform Makes High-Performance Mass Spectrometry Available to Broad Market
Monday, April 19, 2010 | By DNAmite
SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq :SQNM - News) today announced the launch of its next-generation mass spectrometry system – the MassARRAY® Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance. With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases.
But equipment is not something, which will make this company's sales explode. We are all waiting for the Down's Syndrome test announcement.
www.sequenom.com
But equipment is not something, which will make this company's sales explode. We are all waiting for the Down's Syndrome test announcement.
www.sequenom.com
Sequence Pro - Hello World!
Thursday, April 15, 2010 | By DNAmite
Genetic sequencing and interpretation is rapidly becoming a vital part of our daily lives. In under a decade sequencing costs came down from hundreds of millions to under $10K and soon the governments and corporations will have to pay to get someone's genome sequenced.
Here we discuss trends, methods and news in sequencing, genetic analysis diagnostics and predictive genetic and epigenetic biomarkers.
Here we discuss trends, methods and news in sequencing, genetic analysis diagnostics and predictive genetic and epigenetic biomarkers.
Blog Archive
Sequencing Links
Followers
